Press Releases
This first-ever clinical study of an FcRn inhibitor in RA showed nipocalimab reduced levels of circulating IgG antibodies, including ACPAs, indicating they may play a key role in driving RA disease activity Nipocalimab demonstrated improvements in primary and secondary endpoints and participants with higher baseline ACPAs had more than twice the placebo adjusted DAS28-CRP remission…
Read More
Agreement is part of Veracyte’s multi-platform strategy for its decentralized IVD tests outside of the U.S. Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov. 7, 2023– Veracyte, Inc. (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Artiva Biotherapeutics, Inc., a clinical stage company with the mission to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced it has been awarded Immunology Innovation of the Year in the third annual BioTech Breakthrough Awards program, which conducts the…
Read More
Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, today announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines. The publication in the journal mBio is titled “mRNAs encoding…
Read MorePoster also details clinical readiness for CLDI-201 and plans to initiate Phase 1 study in 2024 Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of new preclinical data from the company’s CLD-201 (SuperNova)…
Read More
Phase 1 trial underway for Terns’ first oral GLP-1R agonist candidate for obesity, with 28-day proof of concept data anticipated in 2H24 Oral GLP-1R agonist offers potential for weight loss and improved convenience compared to currently marketed injectables Excerpt from the Press Release: FOSTER CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc.…
Read More
Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting KB-0742 demonstrated on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients with transcriptionally addicted solid tumors …
Read More
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Data further supports the continued clinical advancement of TIDAL-01, Turnstone’s lead Selected TIL therapy, currently being evaluated in two Phase 1 trials Results also demonstrate the potential for a streamlined and…
Read More
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug – – Anti-CCR8 antibody, CHS-114, depletes tumor-infiltrating Treg cells and activates NK cells in dissociated head and neck squamous cell carcinoma (HNSCC) tumors – – Anti-PD-1 antibody, LOQTORZI™ (toripalimab-tpzi), exhibits potent T cell activation; in combination with…
Read More
Excerpt from the Press Release: LA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in…
Read More